Pembrolizumab for the first-line treatment of non-small cell lung cancer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors such as pembrolizumab, a monoclonal antibody that prevents programmed death protein 1 (PD-1) receptor, have brought a paradigm shift in this field. Areas covered: In this article, we review the relevant literatures and ongoing trials on the first-line treatment of pembrolizumab. Especially, in two pivotal phase III trials, KEYNOTE-024 and −189, both pembrolizumab monotherapy and combined pembrolizumab plus chemotherapy significantly prolonged overall survival (OS) compared to the existing platinum-based chemotherapy. Currently, multiple trials with combination therapy of pembrolizumab and other agents have been conducted, and further evidences are expected to be created. Expert opinion: Immune checkpoint inhibitors that block the PD-1/PD-L1 pathway are essential drugs for advanced or recurrent NSCLC, among which pembrolizumab becomes one of the standards of care in the first-line of NSCLC. For further improvement in efficacy of pembrolizumab, it is necessary to clarify the identification of biomarkers exclusive to PD-L1 expression, predictive factors for patients who benefit most from the agent.

Original languageEnglish
Pages (from-to)1015-1021
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume18
Issue number10
DOIs
Publication statusPublished - Oct 3 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cells
Chemotherapy
Platinum
Drug Therapy
Therapeutics
Essential Drugs
Expert Testimony
Biomarkers
Standard of Care
pembrolizumab
Proteins
Monoclonal Antibodies
Survival

Keywords

  • checkpoint inhibitors
  • first-line
  • non-small cell lung cancer
  • PD-L1
  • Pembrolizumab

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Pembrolizumab for the first-line treatment of non-small cell lung cancer. / Ninomiya, Kiichiro; Hotta, Katsuyuki.

In: Expert Opinion on Biological Therapy, Vol. 18, No. 10, 03.10.2018, p. 1015-1021.

Research output: Contribution to journalArticle

@article{09835c2b11da42b9a165755d14988435,
title = "Pembrolizumab for the first-line treatment of non-small cell lung cancer",
abstract = "Introduction: Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors such as pembrolizumab, a monoclonal antibody that prevents programmed death protein 1 (PD-1) receptor, have brought a paradigm shift in this field. Areas covered: In this article, we review the relevant literatures and ongoing trials on the first-line treatment of pembrolizumab. Especially, in two pivotal phase III trials, KEYNOTE-024 and −189, both pembrolizumab monotherapy and combined pembrolizumab plus chemotherapy significantly prolonged overall survival (OS) compared to the existing platinum-based chemotherapy. Currently, multiple trials with combination therapy of pembrolizumab and other agents have been conducted, and further evidences are expected to be created. Expert opinion: Immune checkpoint inhibitors that block the PD-1/PD-L1 pathway are essential drugs for advanced or recurrent NSCLC, among which pembrolizumab becomes one of the standards of care in the first-line of NSCLC. For further improvement in efficacy of pembrolizumab, it is necessary to clarify the identification of biomarkers exclusive to PD-L1 expression, predictive factors for patients who benefit most from the agent.",
keywords = "checkpoint inhibitors, first-line, non-small cell lung cancer, PD-L1, Pembrolizumab",
author = "Kiichiro Ninomiya and Katsuyuki Hotta",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/14712598.2018.1522300",
language = "English",
volume = "18",
pages = "1015--1021",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Pembrolizumab for the first-line treatment of non-small cell lung cancer

AU - Ninomiya, Kiichiro

AU - Hotta, Katsuyuki

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Introduction: Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors such as pembrolizumab, a monoclonal antibody that prevents programmed death protein 1 (PD-1) receptor, have brought a paradigm shift in this field. Areas covered: In this article, we review the relevant literatures and ongoing trials on the first-line treatment of pembrolizumab. Especially, in two pivotal phase III trials, KEYNOTE-024 and −189, both pembrolizumab monotherapy and combined pembrolizumab plus chemotherapy significantly prolonged overall survival (OS) compared to the existing platinum-based chemotherapy. Currently, multiple trials with combination therapy of pembrolizumab and other agents have been conducted, and further evidences are expected to be created. Expert opinion: Immune checkpoint inhibitors that block the PD-1/PD-L1 pathway are essential drugs for advanced or recurrent NSCLC, among which pembrolizumab becomes one of the standards of care in the first-line of NSCLC. For further improvement in efficacy of pembrolizumab, it is necessary to clarify the identification of biomarkers exclusive to PD-L1 expression, predictive factors for patients who benefit most from the agent.

AB - Introduction: Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, immune checkpoint inhibitors such as pembrolizumab, a monoclonal antibody that prevents programmed death protein 1 (PD-1) receptor, have brought a paradigm shift in this field. Areas covered: In this article, we review the relevant literatures and ongoing trials on the first-line treatment of pembrolizumab. Especially, in two pivotal phase III trials, KEYNOTE-024 and −189, both pembrolizumab monotherapy and combined pembrolizumab plus chemotherapy significantly prolonged overall survival (OS) compared to the existing platinum-based chemotherapy. Currently, multiple trials with combination therapy of pembrolizumab and other agents have been conducted, and further evidences are expected to be created. Expert opinion: Immune checkpoint inhibitors that block the PD-1/PD-L1 pathway are essential drugs for advanced or recurrent NSCLC, among which pembrolizumab becomes one of the standards of care in the first-line of NSCLC. For further improvement in efficacy of pembrolizumab, it is necessary to clarify the identification of biomarkers exclusive to PD-L1 expression, predictive factors for patients who benefit most from the agent.

KW - checkpoint inhibitors

KW - first-line

KW - non-small cell lung cancer

KW - PD-L1

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85053515820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053515820&partnerID=8YFLogxK

U2 - 10.1080/14712598.2018.1522300

DO - 10.1080/14712598.2018.1522300

M3 - Article

C2 - 30207786

AN - SCOPUS:85053515820

VL - 18

SP - 1015

EP - 1021

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -